Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2024 | Treosulfan vs busulfan conditioning in pediatric patients with non-malignant diseases

Rita Beier • 15 Apr 2024
EBMT 2024
Non-Malignant Busulfan Treosulfan

Rita Beier, MD, Hannover Medical School, Hannover, Germany, presents the 36-month follow-up data from a Phase II trial comparing treosulfan with busulfan-based conditioning in children with non-malignant diseases. The overall survival (OS) was greater with the treosulfan regimen; however, an increased incidence of secondary graft failure was observed. Dr Beier highlights that, with further optimization of the regimen to reduce secondary graft failure, treosulfan conditioning is safe and efficacious in this patient population. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Rita Beier

2:32
Preventative therapeutic phlebotomies for patients with EPP
Rita Beier • 15 Apr 2024

Related Videos

2:34
A national physician survey investigating the management of pulmonary thromboembolism in pregnancy
Giulia Simini • 29 Apr 2024
1:39
Considering the use of gene therapy in severe inherited thrombophilia
Beverley Hunt • 29 Apr 2024
3:11
The therapeutic implications of shared pathophysiology in classical ITP and other thrombocytopenias
Simona Pagliuca • 24 Apr 2024
2:01
The MDT in the new era of gene therapy for hemoglobinopathies
Mattia Algeri • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals